Seoul, Republic of South Korea – September 14, 2026 – Johnson & Johnson (J&J) has unveiled groundbreaking Phase III PAPILLON study data, showcasing an unprecedented median overall survival (OS) of 34.3 months for its bispecific antibody, Rybrevant (amivantamab-vmjw), in combination with chemotherapy, for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. This landmark achievement, presented at the prestigious Presidential Symposium of the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), marks a significant paradigm shift in the treatment landscape for this historically challenging patient population.

The combination therapy demonstrated a remarkable extension of median OS by over six months compared to chemotherapy alone, which yielded a median OS of 27.9 months. This improvement is particularly striking given that a substantial 76% of eligible patients in the chemotherapy arm subsequently received Rybrevant as a second-line treatment after experiencing disease progression. Even after accounting for this crossover, a prespecified analysis revealed a significant 43% reduction in the risk of death associated with the Rybrevant-chemotherapy combination.

J&J asserts that this represents the longest reported median OS for patients with EGFR Ex20ins-mutated NSCLC, nearly doubling the historical median survival rates previously observed for this aggressive subtype. The durability of this treatment approach was further underscored by comments from leading oncologists, who highlighted the sustained benefits experienced by patients.

Table of Contents

A New Era of Treatment for EGFR Exon 20 Insertions

EGFR Ex20ins mutations, while representing a smaller fraction (approximately 12%) of all EGFR mutations in NSCLC, have long been a vexing challenge for clinicians. Historically, these mutations have been notoriously resistant to traditional EGFR tyrosine kinase inhibitors (TKIs), leading to poorer prognoses and limited treatment options. The median OS for this patient group has typically ranged from 16 to 24 months, with a grim five-year survival rate of just 8%.

The PAPILLON study, a pivotal Phase III trial (NCT04538664), was designed to rigorously evaluate the efficacy and safety of Rybrevant in combination with chemotherapy as a first-line treatment for patients with advanced NSCLC and EGFR Ex20ins mutations. The study’s primary endpoint was progression-free survival (PFS), which was met with overwhelming success. The initial analysis, presented in October 2023, demonstrated a statistically significant and clinically meaningful 60% improvement in PFS for the Rybrevant-chemotherapy arm, achieving a median PFS of 11.4 months compared to 6.7 months in the chemotherapy-only arm.

The newly presented OS data serve as a powerful testament to the enduring impact of this combination therapy, extending beyond the initial progression-free benefit. This indicates that Rybrevant not only delays disease progression but also contributes to a longer overall lifespan for patients.

Chronology of a Breakthrough

The journey of Rybrevant in treating advanced NSCLC with EGFR Ex20ins mutations has been marked by significant milestones:

October 2023: The primary analysis of the Phase III PAPILLON study is presented, revealing a statistically significant improvement in progression-free survival (PFS) for the Rybrevant plus chemotherapy combination compared to chemotherapy alone. This success met the trial’s primary endpoint.

October 2023 onwards: Following the positive PFS data, attention turned to the crucial overall survival (OS) endpoint, a key indicator of long-term patient benefit.

September 12-15, 2026: The IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of South Korea, becomes the stage for the presentation of the landmark OS data from the PAPILLON study. This presentation occurs during the highly anticipated Presidential Symposium, underscoring the significance of the findings.

September 14, 2026 (reported): News breaks detailing the unprecedented median OS of 34.3 months achieved by the Rybrevant plus chemotherapy combination, positioning it as a new standard of care for this patient population.

This timeline highlights the systematic progression of clinical research, moving from initial efficacy signals to definitive evidence of life-extending benefits, culminating in the recognition of this combination as a transformative treatment option.

Supporting Data: Unpacking the PAPILLON Trial Results

The PAPILLON study enrolled patients with advanced NSCLC who had confirmed EGFR Ex20ins mutations and had not received prior systemic therapy for their metastatic disease. The trial randomly assigned patients to receive either Rybrevant (10 mg/kg weekly for four weeks, then every three weeks) plus a platinum-based chemotherapy, or platinum-based chemotherapy alone.

J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC

The key findings from the PAPILLON study are as follows:

Median Overall Survival (OS):n
- Rybrevant + Chemotherapy: 34.3 months
- Chemotherapy Alone: 27.9 months
- Difference: 6.4 months improvement

Risk of Death Reduction (accounting for crossover): 43%

Median Progression-Free Survival (PFS):n
- Rybrevant + Chemotherapy: 11.4 months
- Chemotherapy Alone: 6.7 months
- Improvement: 60%
Crossover Analysis: 76% of patients in the chemotherapy arm crossed over to receive Rybrevant after disease progression. Despite this, the Rybrevant arm demonstrated superior OS, highlighting the potent and durable benefits of the combination.
Safety Profile: The safety profile of intravenous Rybrevant in combination with chemotherapy remained consistent with previously reported studies. The most common treatment-related adverse events (TEAEs) observed were paronychia (inflammation around the fingernail or toenail), neutropenia (low white blood cell count), and rash. These side effects were generally manageable and consistent with known toxicities of the individual agents.

These robust data provide compelling evidence for the superiority of the Rybrevant-chemotherapy combination over chemotherapy alone in extending the lives of patients with EGFR Ex20ins-mutated NSCLC. The significant OS benefit, even in the presence of crossover, underscores the profound impact of this regimen as a first-line treatment.

Official Responses: A Paradigm Shift Acknowledged

The presentation of these groundbreaking results has been met with significant enthusiasm and optimism from the medical community and oncology experts.

Dr. Chul Kim, Director of Thoracic Oncology at MedStar Georgetown University Hospital and an investigator in the PAPILLON study, expressed his profound satisfaction with the findings: "We’ve come a long way in treating EGFR Ex20ins-positive lung cancer, and these results demonstrate the lasting impact RYBREVANT plus chemotherapy can have in helping patients live longer. Patients are continuing treatment years after they started, which speaks to the durability of this approach and its value as a first-line treatment for this disease."

Dr. Kim’s statement emphasizes not only the survival benefit but also the quality of life and sustained response observed in patients receiving the combination therapy. The fact that patients are able to remain on treatment for extended periods suggests a favorable tolerability profile and a sustained ability of the therapy to control disease progression.

Johnson & Johnson has also been a strong advocate for the transformative potential of Rybrevant. The company’s commitment to advancing the treatment of NSCLC, particularly for historically underserved mutations like EGFR Ex20ins, is evident in its continued investment in research and development. J&J has previously secured regulatory approval for Rybrevant in patients with EGFR-mutated advanced NSCLC, encompassing both common mutations (exon 19 deletions and exon 21 L858R substitution mutations) and Ex20ins mutations, in both first- and second-line settings. These new data from the PAPILLON study further solidify Rybrevant’s position as a cornerstone therapy.

Implications for the Future of NSCLC Treatment

The implications of the PAPILLON study’s OS results are far-reaching and are poised to reshape the standard of care for EGFR Ex20ins-mutated NSCLC.

New First-Line Standard of Care: The demonstration of superior and durable OS strongly supports the adoption of Rybrevant plus chemotherapy as the preferred first-line treatment for patients diagnosed with this specific genetic alteration. This will move away from historical approaches that offered limited efficacy.
Improved Patient Outcomes and Quality of Life: By extending survival significantly, the combination therapy offers patients more time with their loved ones and potentially more opportunities for continued treatment and management of their disease. The manageable safety profile further contributes to a better overall patient experience.
Expansion of Targeted Therapy Success: This success underscores the growing understanding of the molecular drivers of NSCLC and the power of targeted therapies. It provides a beacon of hope for patients with other rare or historically difficult-to-treat mutations, encouraging further research into tailored treatment strategies.
Market Growth and Economic Impact: The lung cancer therapeutics market is substantial and projected for significant growth. According to a GlobalData report, the NSCLC therapeutics market across seven major markets was valued at $24.1 billion in 2022 and is forecast to reach $56.5 billion by 2032, with a compound annual growth rate (CAGR) of 8.9%. The approval and widespread adoption of Rybrevant in this new indication will undoubtedly contribute to this market expansion, offering a much-needed therapeutic option and driving innovation.
Future Research Directions: The success of this bispecific antibody combined with chemotherapy may pave the way for further investigations into novel combination strategies, potentially involving immunotherapy or other targeted agents, to further enhance outcomes for NSCLC patients.

In conclusion, Johnson & Johnson’s Rybrevant, in combination with chemotherapy, has achieved a monumental milestone in the fight against advanced NSCLC with EGFR Exon 20 insertion mutations. The unprecedented median overall survival demonstrated in the PAPILLON study not only offers a significant extension of life for patients but also represents a profound advancement in personalized oncology, offering renewed hope and a brighter future for those battling this challenging disease.